RxDoctor Payments Data

Balaji Pratap, MD

Cardiovascular Disease · Middletown, NYNPI 1063725471

Payments from drug & device makers

$6,827in general payments, 2019–2025

Across 249 payments — averaging $27.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$933
  • Kestra Medical Technology Services, Inc.$694
  • Novartis$654
  • Novo Nordisk$429
  • Boehringer Ingelheim$404
  • Boston Scientific$383
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$6,827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,827 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$1,283,053
Medicare patients
1,740
Services billed
10,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$73,393
EntrestoSacubitril/Valsartan14$21,364
XareltoRivaroxaban12$18,867
FarxigaDapagliflozin Propanediol16$13,597
Valsartan67$1,740
Metoprolol Succinate73$1,167
Labetalol Hcl29$968
Atorvastatin Calcium57$850
Midodrine Hcl13$730
Nifedipine ErNifedipine21$597
Torsemide25$501
Losartan Potassium34$313
ClopidogrelClopidogrel Bisulfate25$310
Amiodarone Hcl16$306
Propranolol Hcl19$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$195$73,39358 claims
NovartisEntresto$654$21,36414 claims
Johnson & JohnsonXarelto$379$18,86712 claims
AstraZenecaFarxiga$933$13,59716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →